Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States

Journal of Medical Economics

Volumn 15, Issue 3, 2012, Pages 531-547

  Ascher Svanum, Haya ^a   Furiak, Nicolas M ^b   Lawson, Anthony H ^a   Klein, Timothy M ^b   Smolen, Lee J ^b   Conley, Robert R ^a   Culler, Steven D ^c  

^a ELI LILLY AND COMPANY   (United States)

^b Medical Decision Modeling Inc   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Antipsychotics; Cost effectiveness; Olanzapine; Orally disintegrating

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; MONTE CARLO METHOD; PATIENT COMPLIANCE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RELAPSE; SCHIZOPHRENIA; SIDE EFFECT; TABLET; UNITED STATES; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; HUMANS; MONTE CARLO METHOD; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; QUALITY-ADJUSTED LIFE YEARS; SCHIZOPHRENIA; TABLETS; UNITED STATES;

EID: 84859191454     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.662923     Document Type: Article

References (47)

1. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201
2. Ascher-Svanum H, Zhu B, Faries D, et al. A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry 2004;3:11
3. Law MR, Soumerai SB, Ross-Degnan D, et al. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry 2008;69:47-53
4. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care 2002;40:630-9
5. Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull 2008;34:173-80
6. Chue P, Jones B, Taylor CC, et al. Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia. Can J Psychiatry 2002;47:771-4
7. Keith S. Advances in psychotropic formulations. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:996-1008
8. Wertheimer AI, Santella TM, Finestone AJ, et al. Drug delivery systems improve pharmaceutical profile and facilitate medication adherence. Adv Ther 2005;22:559-77
9. Bogner RH, Wilkosz MF. Fast-dissolving tablets: New dosage convenience for patients. US Pharmacist 2002;27:34-43
10. Kuchekar BS, Badhan AC, Mahajan HS. Mouth dissolving tablets: A novel drug delivery system. Pharma Times 2003;35:7-9
11. Kinon BJ, Hill AL, Liu H, et al. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. Int J Neuropsychopharmacol 2003;6:97-102
12. Czekalla J, Wagner T, Schact A, et al. Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients. Patient Prefer Adherence 2007;1:19-27
13. Karagianis J, Grossman L, Lee B, et al. A 16-week, randomized, double-blind, double-dummy trial of sublingual orally disintegrating olanzapine vs standard olanzapine tablets in patients who gained weight during olanzapine. Schizophr Res 2008;102:Suppl 2. http://www.sciencedirect.com/science/article/ pii/S0920996408707175 [Accessed February 2012]
14. Ciorabai EM, Oyffe I, Dilbaz N, et al. Patients preference of olanzapine orodipersible tablets compared with olanzapine classic oral tablet in a multinational randomized crossover study. Eur Psychiatry 2008; 23(2 Suppl):S150-1
15. San L, Casillas M, Ciudad A, et al. Olanzapine orally disintegrating tablet: A review of efficacy and compliance. CNS Neurosci Ther 2008;14:203-14
16. Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc 2009;7:4
17. Bettonvil B, Kleijnen JPC. Searching for important factors in simulation models with many factors: Sequential bifurcation. Eur J Oper Res 1997; 96:180-94
18. Zhao Z. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia. Manag Care Interface 2002;15:75-81
19. Rascati KL, Johnsrud MT, Crismon ML, et al. Olanzapine versus risperidone in the treatment of schizophrenia: A comparison of costs among Texas Medicaid recipients. Pharmacoeconomics 2003;21:683-97
20. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-9
21. Gibson PJ, Damler R, Jackson EA, et al. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population. Value Health 2004;7:22-35
22. Ascher-Svanum H, Zhu B, Faries DE, et al. Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Prefer Adherence 2008;2:67-77
23. Ascher-Svanum H, Zhu B, Faries DE, et al. Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Res Notes 2009;2:6
24. Karagianis J, Grossman L, Landry J, et al. A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: The PLATYPUS Study. Schizophr Res 2009;113:41-8
25. Ahn J, McCombs JS, Jung C, et al. Classifying patients by antipsychotic adherence patterns using latent class analysis: Characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program. Value Health 2008;11:48-56
26. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-23
27. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia [Erratum]. N Engl J Med 2010;363:1092-3
28. Zimbroff D, Warrington L, Loebel A, et al. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, 4-week study. Int Clin Psychopharmacol 2007;22:363-70
29. Agency for Healthcare Research and Quality (AHRQ). HCUP Nationwide Inpatient Sample (NIS), 2004. Healthcare Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality. Rockville, MD: AHRQ, 2004. http://hcupnet.ahrq.gov/HCUPnet.jsp. [Accessed 9 December 2010]
30. Olfson M, Mechanic D, Hansell S, et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;51:216-22
31. Tiihonen J, Wahlbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: Observational follow-up study. BMJ 2006;333:224
32. Edwards NC, Locklear JC, Rupnow MF, et al. Cost effectiveness of longacting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005; 23(1 Suppl):75-89
33. Siris SG. Suicide and schizophrenia. J Psychopharmacol 2001; 15:127-35
34. Lambert BL, Cunningham FE, Miller DR, et al. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am J Epidemiol 2006;164:672-81
35. Fleischhacker WW, McQuade RD, Marcus RN, et al. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry 2009;65:510-7
36. Carlson CD, Cavazzoni PA, Berg PH, et al. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: Comparisons with placebo, haloperidol, risperidone, or clozapine. J Clin Psychiatry 2003;64:898-906
37. Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 2004;71:155-65
38. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-74
39. Kern RS, Green MF, Cornblatt BA, et al. The neurocognitive effects of aripiprazole: An open-label comparison with olanzapine. Psychopharmacology (Berl) 2006;187:312-20
40. Analysource Data. AWP/NWP cost of antipsychotics. www.Analysource.com. Accessed December 9, 2010
41. Tunis SL, Faries DE, Nyhuis AW, et al. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: Results from a randomized, open-label, 1-year trial. Value Health 2006;9:77-89
42. Bureau of Labor Statistics. Consumer Price Index - Medical Services Component. United States Department of Labor, 2010. http://data.bls.gov/cgi-bin/ surveymost?cu. Accessed 6 September 2011
43. Vera-Llonch M, Delea TE, Richardson E, et al. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: A Markov model. Value Health 2004;7: 569-584
44. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-49
45. drugstore.com. 2011. http://www.drugstore.com/pharmacy/prices/drugprice. asp?ndc00006074954&trx1Z5006; Accessed 7 September 2011
46. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-To-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009;166:152-63
47. Ascher-Svanum H, Stensland MD, Peng X, et al. Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. Curr Med Res Opin 2011;27:115-22